Recommendations made by the PBAC – March 2022
Page last updated: 30 July 2024
Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2022 relating to the listing of drugs on the Pharmaceutical Benefits Scheme (PBS).
- Home
- PBS Information
- About the PBS
- PBS Contacts
- Latest News
- Subscribe to PBS News
- Frequently asked questions
- Pharmaceutical Benefits Advisory Committee (PBAC)
- Medicine Status
- Eighth Community Pharmacy Agreement (8CPA)
- PBS Process Improvements
- Biosimilars on the PBS
- PBS Publications
- PBS Downloads
- PBS Reviews
- PBS Statistics
- Committees
- Working Groups
- Report adverse drug reactions
- PBS Mobile website
- PBS Software Developers
- Browse the PBS
- New,amended and deleted
- 60-day prescriptions
- A-Z medicine listing
- Biological Medicines
- Body system
- Botulinum Toxin Program
- Continued Dispensing Arrangements
- Dental Items
- Efficient Funding of Chemotherapy
- Growth Hormone Program
- Highly Specialised Drugs Program
- IVF Program
- Manufacturer / Supplier
- Midwife Items
- Nurse Practitioner Items
- Opioid Dependence Treatment Program
- Optometrical Items
- Palliative Care Items
- Prescriber Bag Supplies
- Repatriation (RPBS)
- Safety Net early supply
- Section 100
- Streamlined Authorities
- Supply Only
- Therapeutic group
- Explanatory notes
- Price Premiums
- For Health Professionals
- For Industry
- News
- Publications & Downloads
- Contacts
